Merck Serono initiates Phase III Cladribine Trial

The trial, called Oracle MS, will evaluate the safety and efficacy of two dosage regimens of cladribine tablets versus placebo in the treatment of patients who have experienced a first clinical event suggestive of multiple sclerosis (MS). Cladribine tablets are currently also being evaluated in a fully enrolled Phase III pivotal trial - the Clarity study - for treatment of relapsing forms of MS.

Info on current MS/Cladribine trials is here.